- $6.05bn
- $5.19bn
- $147.17m
Brief: Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
EU regulators scrap merger power aimed at killer acquisitions after court veto
Brief: Grail Presents Initial Results From Reflection Real-World Evidence Study Of Galleri® Multi-Cancer Early Detection (Mced) Test
Deals of the day-Mergers and acquisitions
Newscasts - Trading at Noon: U.S. manufacturing edges up in August, but the trend remains weak
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Illumina wins Grail battle in blow to EU merger power (updated)
EU top court backs Illumina fight against EU probe into Grail deal
Brief: Soros Fund Management Reports Share Stake In Grail & Unitedhealth Group ,Raises In Merck & Co, Nike
Cancer test maker Grail rises on job cuts
Advisory: Incorrect alert on Bluebet Holdings' turnover withdrawn
Grail climbs on job cuts
Cancer test maker Grail cuts 350 jobs as part of restructuring program (updated)
Grail to cut jobs, planned hires for 2024 by about 30%
Illumina expects full-year sales from core segment to decline on biotech funding crunch
Analysis: With no big deal safe, investment bankers move to safeguard fees
Brief: Grail Announces First Participant Enrolled In Reach Study Evaluating Clinical Impact Of Galleri® Multi-Cancer Early Detection (Mced) Test In The Medicare Population
Nasdaq biotech index hits over 2-1/2 yr high